ANTIGENIC EXPRESSION OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIC-CELL LINES

被引:6
|
作者
MARTI, GE
ZENGER, V
BROWN, M
MARTI, DM
MELO, JV
CRESCENZI, M
DADEY, B
HAN, T
BERTIN, P
CAPORASO, NE
NOGUCHI, P
机构
[1] Laboratory of Cellular and Molecular Biology, Division of Biochemistry and Biophysics, Bethesda, MD
[2] Immunology Service, CPD, CC, NIH, Bethesda, MD
[3] Department of Biology, Hood College, Frederick, MD
[4] Department of Haematology, MRC/LAF Leukaemia Unit, Royal Postgraduate Medical School, London
[5] Dipartimento di Biologia Cellulare e dello Svilippo, Universita' di Roma La Sapienza, Rome
[6] Department of Medical Oncology, Roswell Park Memorial Institute, Buffalo, NY
[7] Family Studies Section, Epidemiology and Biostatistics Program, NCI, NIH, Maryland
关键词
B-CLL LEUKEMIC CELL LINES ANTIGENIC EXPRESSION;
D O I
10.3109/10428199209049807
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A flow cytometric analysis of five B cell chronic lymphocytic leukemic (B-CLL) cell lines was undertaken using 129 unknown reagents from the blind panel (BP) and 72 reagents from the known CD panel obtained from the Fourth International Leucocyte Differentiation Conference and Workshop, B cell section (Vienna, 1989). The five cell lines examined were: SeD (PNAS 75, 5706, 1978), B-CLL-LCL (BLOOD 71, 9, 1988), JVM-HH and JVM-2(INT J CAN 38, 531, 1986), and WR # 1 (TH and BD). The reagents were # 1-129 (blinded panel) and reagents 1-44 and 53-84 (CD panel with CD23 reagents missing). Positivity was defined as greater than 30% of the cells having a three fold increase or more in mean channel fluorescence. Fourty-three reagents of the blinded panel were negative by these criteria while all remaining reagents were positive on all five lines. SeD showed the lowest reactivity; B-CLL-LCL and JVM-2 showed the most reactivity; JVM-HH and WR # 1 were intermediate. The known CD panel confirmed the reactivity of the blinded panel. An average immunophenotype was constructed and compared to published normal EBV lymphoblastoid cell lines and several differences were noted. There was an absence or significant decrease in the expression of CD19, CD21, CD22 and CD37 while there was an increased expression of CD38, CD54, CD74 and CD76. The heterogeneity observed between the B-CLL lines may in part be due to polymorphisms but is more likely to represent the underlying heterogeneity seen in common and familial B-CLL. In addition the variation in CD expression may be related to the effects of EBV transformation.
引用
收藏
页码:497 / 504
页数:8
相关论文
共 50 条
  • [31] Greater in vivo B-cell chronic lymphocytic leukemia cell turnover is associated with progressive leukemic burden.
    Messmer, BT
    Messmer, D
    Allen, SL
    Rai, KR
    Hellerstein, M
    Chiorazzi, N
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (02) : S382 - S382
  • [32] B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia
    Marti, GE
    Carter, P
    Abbasi, F
    Washington, GC
    Jain, N
    Zenger, VE
    Ishibe, N
    Goldin, L
    Fontaine, L
    Weissman, N
    Sgambati, M
    Fauget, G
    Bertin, P
    Vogt, RF
    Slade, B
    Noguchi, PD
    Stetler-Stevenson, MA
    Caporaso, N
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2003, 52B (01) : 1 - 12
  • [33] Rituximab in B-cell chronic lymphocytic leukemia
    Lin, TS
    Lucas, MS
    Byrd, JC
    SEMINARS IN ONCOLOGY, 2003, 30 (04) : 483 - 492
  • [34] Alemtuzumab in B-cell chronic lymphocytic leukemia
    Shapira, I
    Grossbard, ML
    CLINICAL LYMPHOMA, 2004, 4 (04): : 228 - 229
  • [35] Alemtuzumab for B-cell chronic lymphocytic leukemia
    Robak, Tadeusz
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1033 - 1051
  • [36] Histopathology of B-cell chronic lymphocytic leukemia
    Pileri, SA
    Sabattini, E
    Agostinelli, C
    Bodega, L
    Rossi, M
    Zinzani, PL
    Marafioti, T
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (04) : 807 - +
  • [37] The origin of B-cell chronic lymphocytic leukemia
    Ghia, P
    Caligaris-Cappio, F
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : 150 - 156
  • [38] MICROPARTICLE RELEASE FROM PLATELETS BY LEUKEMIC-CELL LINES
    NOMURA, S
    MIYAKE, T
    MIYAZAKI, Y
    KIDO, H
    YAMAGUCHI, K
    KAGAWA, H
    SUZUKI, M
    YANABU, M
    KOKAWA, T
    KOMIYAMA, Y
    TAKAHASHI, H
    FUKUHARA, S
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1994, 52 (04) : 254 - 255
  • [39] ALTERATIONS IN DEPENDENCE ON LIPOXYGENASE METABOLISM IN LEUKEMIC-CELL LINES
    MILLER, AM
    CULLEN, MK
    KOBB, SM
    WEINER, RS
    EXPERIMENTAL HEMATOLOGY, 1988, 16 (06) : 419 - 419
  • [40] Extensive leukemic kidney infiltration with membranoproliferative glomerulonephritis in a patient with B-cell chronic lymphocytic leukemia
    Kiewe, Philipp
    Tepel, Martin
    Loddenkemper, Christoph
    Gruenbaum, Maria
    Grabowski, Patricia
    Korfel, Agnieszka
    Thiel, Eckhard
    ANNALS OF HEMATOLOGY, 2007, 86 (09) : 691 - 692